Despite Shanghai ZJ Bio-Tech's poor revenue, its P/S ratio a...
Despite Shanghai ZJ Bio-Tech's poor revenue, its P/S ratio aligns with the industry, indicating investors might be ignoring recent negative growth and hoping for a business turnaround. However, if medium-term revenue trends persist, this could risk shareholders' investments and potential investors might pay an unnecessary premium.
![](https://pubimg-10000538.picsh.myqcloud.com/202205090000017806c005a67f7.jpg)
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment